Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
156 studies found for:    Open Studies | "Blood Platelet Disorders"
Show Display Options
Rank Status Study
21 Recruiting Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.
Condition: Thrombocytopenia
Intervention: Drug: Eltrombopag
22 Not yet recruiting Study on the Anti-HPA Antibodies Caused Neonatal Alloimmune Thrombocytopenia in Chinese Pregnant Women
Condition: Neonatal Alloimmune Thrombocytopenia
Intervention: Procedure: Standard clinical treatment, including intravenous immunoglobulin and/or platelet transfusion
23 Recruiting Mathematical Modeling to Predict the Duration of Thrombocytopenia in Neonates
Condition: Neonatal Thrombocytopenia
Intervention:
24 Recruiting Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures
Conditions: Chronic Liver Disease;   Thrombocytopenia
Interventions: Drug: Lusutrombopag;   Drug: Placebo
25 Recruiting Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
Condition: Thrombocytopenia Associated With Liver Disease
Interventions: Drug: avatrombopag (lower baseline platelet count);   Drug: placebo (lower baseline platelet count);   Drug: avatrombopag (higher baseline platelet count);   Drug: placebo (higher baseline platelet count)
26 Recruiting Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
Condition: Thrombocytopenia Associated With Liver Disease
Interventions: Drug: avatrombopag (lower baseline platelet count);   Drug: placebo (lower baseline platelet count);   Drug: avatrombopag (higher baseline platelet count);   Drug: placebo (higher baseline platelet count)
27 Recruiting Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants
Conditions: Thrombotic Microangiopathy;   Disorder Related to Bone Marrow Transplantation
Intervention: Drug: eculizumab
28 Not yet recruiting Screening of TMA Patients für ADAMTS13 Activity (Adamscreen)
Condition: Thrombotic Microangiopathies
Intervention: Biological: Technozyme
29 Available OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy
Condition: Thrombotic Microangiopathy
Intervention: Biological: OMS721
30 Recruiting Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies
Condition: Thrombotic Microangiopathies
Intervention: Biological: OMS721
31 Recruiting Molecular Biology of Polycythemia and Thrombocytosis
Conditions: Polycythemia;   Thrombocytosis
Intervention:
32 Recruiting Observational Trial of a Therapeutic Platelet Transfusion Regimen
Conditions: Acute Myeloid Leukemia;   Thrombocytopenia
Intervention:
33 Recruiting Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia
Conditions: Antineoplastic Adverse Reaction;   Thrombocytopenia;   Acute Myelocytic Leukemia
Intervention: Drug: rhTPO
34 Not yet recruiting Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Biological: RNA sample of total leukocytes before start of treatment
35 Recruiting Familial Myeloproliferative Disorders
Conditions: Polycythemia Vera;   Essential Thrombocythemia;   Idiopathic Myelofibrosis
Intervention:
36 Recruiting Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE
Condition: Thrombocytopenia
Interventions: Drug: Hydroxychloroquine;   Drug: Cyclophosphamide;   Drug: Azathioprine;   Drug: Methylprednisolone
37 Not yet recruiting The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line
Condition: Essential Thrombocythemia
Interventions: Drug: Anagrelide;   Drug: Ruxolitinib (JAKAVI®);   Drug: IFNα/ PegIFNα
38 Not yet recruiting Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia
Conditions: MPN;   Essential Thrombocythemia
Interventions: Other: Aspirin therapy interruption;   Other: Usual treatment by aspirin 100 mg/d in the active comparator arm;   Other: No interruption of aspirin in the Observational arm;   Drug: Hydroxyurea treatment (HU)
39 Recruiting Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia
Conditions: Aplastic Anemia;   Neutropenia;   Pancytopenia;   Anemia;   Thrombocytopenia
Interventions: Drug: Eltrombopag;   Drug: Horse Anti-Thymocyte Globulin (ATG);   Drug: Cyclosporine A (CSA)
40 Not yet recruiting Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.
Conditions: Primary Myelofibrosis (PMF);   Post-Polycythemia Vera-Myelofibrosis (PPV-MF);   Post-Essential Thrombocythemia Myelofibrosis (PET-MF)
Intervention: Drug: ruxolitinib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.